Compare · LLY vs SIGA
LLY vs SIGA
Side-by-side comparison of Eli Lilly and Company (LLY) and SIGA Technologies Inc. (SIGA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and SIGA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 5316.8x SIGA ($218.4M).
- LLY has been more active in the news (17 items in the past 4 weeks vs 3 for SIGA).
- LLY has more recent analyst coverage (25 ratings vs 0 for SIGA).
- Company
- Eli Lilly and Company
- SIGA Technologies Inc.
- Price
- -
- -
- Market cap
- $1.16T
- $218.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 17
- 3
- Recent ratings
- 25
- 0
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
SIGA Technologies Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was founded in 1995 and is headquartered in New York, New York.
Latest LLY
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Latest SIGA
- SEC Form 10-Q filed by SIGA Technologies Inc.
- SIGA Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
- SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
- SEC Form S-8 filed by SIGA Technologies Inc.
- Director Marshall Joseph W Iii converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 7% to 246,523 units (SEC Form 4) (withholding tax)
- Director Keane John M converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39) (SEC Form 4) to satisfy withholding obligation
- Director Ford Harold Eugene Jr. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 55% to 47,538 units (SEC Form 4) (withholding obligation)
- Director Phillips Holly L. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) to cover withholding tax
- Director Nemirovsky Julian converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) to satisfy withholding obligation